中药治疗化疗所致白细胞减少症:高质量随机对照试验的系统评价与Meta分析
该系统评价纳入14项高质量随机对照试验共1053例患者,评价中药联合化疗治疗化疗所致白细胞减少症的疗效与安全性。结果显示中药联合化疗在提升白细胞、中性粒细胞、血红蛋白、血小板计数及KPS评分方面优于单纯化疗,在改善白细胞计数、KPS、感染例数、G-CSF使用率及白细胞减少症发生率方面优于西药联合化疗,但与安慰剂联合化疗相比在降低中性粒细胞减少症发生率上无显著差异;14项试验未见严重不良事件。
要点
- 中药联合化疗可改善化疗所致白细胞减少症患者的血细胞计数与KPS评分。
- 与西药联合化疗相比,中药联合化疗在白细胞计数、KPS、感染例数、G-CSF使用率及白细胞减少症发生率方面更优。
- 与安慰剂联合化疗相比,中药联合化疗在降低中性粒细胞减少症发生率上无显著差异。
核心结论
- 与单纯化疗或西药联合化疗相比,中药联合化疗可有效改善化疗所致白细胞减少症的临床症状,但与安慰剂联合化疗相比无显著差异。
- 14项随机对照试验中中药未见严重不良事件,临床使用总体安全。
研究设计与样本
- 共纳入14项随机对照试验,涉及1053例患者,使用RevMan 5.3进行Meta分析。
主要发现
- 中药联合化疗在白细胞、中性粒细胞、血红蛋白、血小板计数及KPS评分方面优于单纯化疗,但在G-CSF剂量上无显著差异。
- 安慰剂联合化疗与中药联合化疗在降低中性粒细胞减少症发生率方面无显著差异。
- 中药联合化疗在改善白细胞计数、KPS、感染例数、G-CSF使用率及白细胞减少症发生率方面优于西药联合化疗。
- 14项随机对照试验中未观察到严重不良事件。
临床怎么用
- 对于化疗所致白细胞减少症患者,可考虑在化疗基础上联用中药以改善血细胞计数与功能状态。
- 与西药联合化疗方案相比,中药联合化疗在白细胞计数、KPS、感染例数、G-CSF使用率及白细胞减少症发生率方面可能更具优势。
- 中药联合化疗总体安全性较好,但仍需更大样本的高质量随机对照试验以降低研究异质性。
局限性
- 研究间存在异质性,需更大样本的高质量随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aim: We conducted a systematic review of high-quality randomized controlled trials (RCTs) to assess the efficacy and safety of Chinese herbal medicine (CHM) for the treatment of chemotherapy-induced leukopenia (CIL). Methods: Eight electronic databases were searched from the date of inception to November 4, 2020 for high-quality RCTs that met the requirements of at least four key domains of the Cochrane risk of bias (RoB) tool. RevMan 5.3 was applied for the meta-analysis. Results: Fourteen RCTs involving 1,053 patients were included. The pooled results showed that CHM + chemotherapy exerted greater beneficial effects on white blood cell (WBC), neutrophil (NEU), hemoglobin (Hb), and platelet (PLT) counts in addition to the Karnofsky performance scale (KPS) score, but showed no significant difference on granulocyte colony-stimulating factor (G-CSF) dosage compared with chemotherapy alone. Placebo (PBO) + chemotherapy and CHM + chemotherapy groups showed no significant differences in terms of reduction of the incidence of neutropenia. CHM + chemotherapy was superior to Western medicine (WM) + chemotherapy in improving the WBC count, KPS, infection amount, G-CSF use rate, and incidence of leukopenia. In addition, no severe adverse events were observed in the 14 RCTs. Conclusion: CHM in combination with chemotherapy could effectively improve the clinical symptoms of CIL when compared with chemotherapy alone or Western medicine + chemotherapy, except when comparing with PBO + chemotherapy. While CHMs were generally safe for clinical use and exerted no severe side effects in the 14 RCTs, high-quality RCTs with larger sample sizes are essential to reduce study heterogeneity.
引用
- Wang Q, Ye H, Wang QQ, et al. Chinese Herbal Medicine for Chemotherapy-Induced Leukopenia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. Front Pharmacol. 2021. PMID: 34017246. doi:10.3389/fphar.2021.573500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。